Indication: SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): 1. 1 Juvenile Idiopathic Arthritis (JIA): 1. 2 Psoriatic Arthritis (PsA): 1. 3 Ankylosing Spondylitis (AS): 1. 4 Crohn’s Disease (CD): 1. 5 Ulcerative Colitis (UC): 1. 6 Limitations of Use: Plaque Psoriasis (Ps): 1. 7 Hidradenitis Suppurativa (HS): 1. 8 Uveitis (UV): 1. 9 SIMLANDI is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. SIMLANDI can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). SIMLANDI is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. SIMLANDI can be used alone or in combination with methotrexate. SIMLANDI is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. SIMLANDI can be used alone or in combination with non-biologic DMARDs. SIMLANDI is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. SIMLANDI is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. SIMLANDI is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14. 7 SIMLANDI is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. SIMLANDI should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 SIMLANDI is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. SIMLANDI is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

Indication: Adalimumab-adaz is a tumor necrosis factor (TNF)-blocker indicated for: Rheumatoid Arthritis (RA) (1. 1) Juvenile Idiopathic Arthritis (JIA) (1. 2) Psoriatic Arthritis (PsA) (1. 3) Ankylosing Spondylitis (AS) (1. 4) Crohn’s Disease (CD) (1. 5) Ulcerative Colitis (UC) ( 1. 6 Limitations of Use Plaque Psoriasis (Ps) ( 1. 7 Hidradenitis Suppurativa (HS) ( 1. 8 Uveitis (UV) ( 1. 9 Adalimumab-adaz is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-adaz can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab-adaz is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-adaz can be used alone or in combination with methotrexate. Adalimumab-adaz is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-adaz can be used alone or in combination with non-biologic DMARDs. Adalimumab-adaz is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. Adalimumab-adaz is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Adalimumab-adaz is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF-blockers [see Clinical Studies (14. 7) Adalimumab-adaz is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-adaz should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) Adalimumab-adaz is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. Adalimumab-adaz is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

Indication: YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) 1. 1 Juvenile Idiopathic Arthritis (JIA) 1. 2 Psoriatic Arthritis (PsA) 1. 3 Ankylosing Spondylitis (AS) 1. 4 Crohn's Disease (CD) 1. 5 Ulcerative Colitis (UC) 1. 6 Limitations of Use: Plaque Psoriasis (Ps) 1. 7 Hidradenitis Suppurativa (HS) 1. 8 Uveitis (UV) 1. 9 YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). YUSIMRY is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUSIMRY can be used alone or in combination with methotrexate. YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUSIMRY can be used alone or in combination with non-biologic DMARDs. YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. YUSIMRY is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. YUSIMRY is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14. 7 YUSIMRY is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUSIMRY should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 YUSIMRY is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. YUSIMRY is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

Indication: Adalimumab-aaty is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1. 1 Juvenile Idiopathic Arthritis (JIA) ( 1. 2 Psoriatic Arthritis (PsA) ( 1. 3 Ankylosing Spondylitis (AS) ( 1. 4 Crohn's Disease (CD) ( 1. 5 Ulcerative Colitis (UC) ( 1. 6 Limitations of Use: Plaque Psoriasis (Ps) ( 1. 7 Hidradenitis Suppurativa (HS) ( 1. 8 Uveitis (UV) ( 1. 9 Adalimumab-aaty is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-aaty can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab-aaty is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-aaty can be used alone or in combination with methotrexate. Adalimumab-aaty is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-aaty can be used alone or in combination with non-biologic DMARDs. Adalimumab-aaty is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. Adalimumab-aaty is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. Adalimumab-aaty is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14. 7) Adalimumab-aaty is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-aaty should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) Adalimumab-aaty is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. Adalimumab-aaty is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

Indication: Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): 1. 1 Juvenile Idiopathic Arthritis (JIA): 1. 2 Psoriatic Arthritis (PsA): 1. 3 Ankylosing Spondylitis (AS): 1. 4 Crohn’s Disease (CD): 1. 5 Ulcerative Colitis (UC): 1. 6 Limitations of Use: Plaque Psoriasis (Ps): 1. 7 Hidradenitis Suppurativa (HS): 1. 8 Uveitis (UV): 1. 9 Adalimumab-ryvk is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab-ryvk is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-ryvk can be used alone or in combination with methotrexate. Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs. Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. Adalimumab-ryvk is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Adalimumab-ryvk is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14. 7 Adalimumab-ryvk is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-ryvk should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 Adalimumab-ryvk is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. Adalimumab-ryvk is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.